Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease

@article{Hockly2006EvaluationOT,
  title={Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease},
  author={Emma Hockly and Jamie Tse and Amy L. Barker and Donna L. Moolman and Gillian P Bates},
  journal={Neurobiology of Disease},
  year={2006},
  volume={21},
  pages={228-236}
}
Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormal protein aggregation and deposition in the brain. Several compounds have been shown to disrupt the aggregation process in vitro, including a number of benzothiazoles. To further explore the therapeutic potential of the benzothiazole aggregation inhibitors, we assessed PGL-135 and riluzole in hippocampal… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

Similar Papers

Loading similar papers…